Charles Darwin University

Nonlinear Mixed-Effects Modelling of In Vitro Drug Susceptibility and Molecular Correlates of Multidrug Resistant Plasmodium falciparum

Simpson, Julie; JAMSEN, K; Anderson, Tim; Zaloumis, Sophie; Nair, Shalini; Woodrow, Charles; White, Nicholas J; Nosten, François; Price, Ric

PLOS ONE

Nonlinear Mixed-Effects Modelling of *In Vitro* Drug Susceptibility and Molecular Correlates of Multidrug Resistant *Plasmodium falciparum*

Julie A. Simpson[1]*, Kris M. Jamsen[1], Tim J. C. Anderson[2], Sophie Zaloumis[1], Shalini Nair[2], Charles Woodrow[3,4,5], Nicholas J. White[3,4], Francois Nosten[3,6], Ric N. Price[3,5,7]

1 Centre for Molecular, Environmental, Genetic & Analytic Epidemiology, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia, 2 Texas Biomedical Research Institute, San Antonio, Texas, United States of America, 3 Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom, 4 Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand, 5 WorldWide Antimalarial Resistance Network (WWARN), Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom, 6 Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand, 7 Global Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia

Abstract

The analysis of *in vitro* anti-malarial drug susceptibility testing is vulnerable to the effects of different statistical approaches and selection biases. These confounding factors were assessed with respect to *pfmdr1* gene mutation and amplification in 490 clinical isolates. Two statistical approaches for estimating the drug concentration associated with 50% effect (EC_{50}) were compared: the commonly used standard two-stage (STS) method, and nonlinear mixed-effects modelling. The *in vitro* concentration-effect relationships for, chloroquine, mefloquine, lumefantrine and artesunate, were derived from clinical isolates obtained from patients on the western border of Thailand. All isolates were genotyped for polymorphisms in the *pfmdr1* gene. The EC_{50} estimates were similar for the two statistical approaches but 15–28% of isolates in the STS method had a high coefficient of variation ($>$15%) for individual estimates of EC_{50} and these isolates had EC_{50} values that were 32 to 66% higher than isolates derived with more precision. In total 41% (202/490) of isolates had amplification of *pfmdr1* and single nucleotide polymorphisms were found in 50 (10%). *Pfmdr1* amplification was associated with an increase in EC_{50} for mefloquine (139% relative increase in EC_{50} for 2 copies, 188% for 3+ copies), lumefantrine (82% and 75% for 2 and 3+ copies respectively) and artesunate (63% and 127% for 2 and 3+ copies respectively). In contrast *pfmdr1* mutation at codons 86 or 1042 were associated with an increase in chloroquine EC_{50} (44–48%). Sample size calculations showed that to demonstrate an EC_{50} shift of 50% or more with 80% power if the prevalence was 10% would require 430 isolates and 245 isolates if the prevalence was 20%. In conclusion, although nonlinear mixed-effects modelling did not demonstrate any major advantage for determining estimates of anti-malarial drug susceptibility, the method includes all isolates, thereby, potentially improving confirmation of candidate molecular markers of anti-malarial drug susceptibility.

Introduction

In vitro drug susceptibility assays provide a means of assessing anti-malarial drug activity. These assays are important tools for monitoring anti-malarial drug resistance, determining the relationship between parasite genetic polymorphisms and drug susceptibility, and quantifying the potency of novel compounds. A variety of methodological approaches have been developed and applied to assessment of laboratory adapted strains of Plasmodium as well as field isolates of *P. falciparum* and *P. vivax* [1–3]. Established assays vary, but in general define a parasites' drug susceptibility by measurements of growth or development *ex vivo* in the constant presence of varying drug concentrations, usually generated by doubling dilutions of the drug under investigation. The standard statistical analysis of such assays focuses on fitting separate nonlinear regression equations to each isolate's concentration-effect data, using a nonlinear Sigmoid Emax equation, deriving four measures: the minimum and maximum effect, the slope (sigmoidicity) of the effect-concentration curve, and the drug concentration that achieves 50% of the maximum effect (termed the EC_{50}). The isolate-specific estimates of these parameters are then combined to calculate summary statistics that describe the population distribution. However this approach, referred to as the standard two-stage (STS) method [4], is vulnerable to a variety of selection biases [5]. Importantly the estimates of highly resistant isolates, often the most interesting parasites, are intrinsically less

precise and thus often rejected [6]. In the case of laboratory isolates drug susceptibility assays can be repeated, however, in field studies repetition of the assay with revised drug concentrations is often not feasible from a fresh sample unless isolates are adapted to continuous culture, a process which may increase selection bias further. Simply excluding these extreme isolates as unreliable skews the population estimates towards a lower population mean EC_{50}.

Nonlinear mixed-effects modelling is an alternative statistical approach for analysing repeated measurement data [7]. When applied to the analysis of *in vitro* drug susceptibility data, information from all of the isolates is analysed simultaneously. Estimates of the population mean values for each of the model parameters are derived, as well as the between-isolate variance of each parameter and the overall within-isolate variance. Although routinely used in sparsely sampled pharmacokinetic studies [8,9], its application to the analysis of data from *in vitro* studies is limited.

On the western border of Thailand multidrug resistance in *P.falciparum* has been shown to correlate with polymorphisms of *pfmdr1*; gene amplification being associated with reduced sensitivity to mefloquine, lumefantrine and artemisinin derivatives [10,11], whereas single nucleotide polymorphisms are associated with chloroquine resistance [12]. In this study, we have pooled a large collection of carefully characterised field isolates from Thailand, to review the *in vitro* – molecular correlates and intra-assay variation using the STS method and nonlinear mixed-effects modelling. The comparison is restricted to four anti-malarial drugs, chloroquine, mefloquine, lumefantrine and artesunate, to evaluate if the more complex and comprehensive method of nonlinear mixed-effects modelling, provides important additional information on the *in vitro* - molecular correlation of antimalarial drug resistance and specifically whether it provides increased statistical power for detecting shifts in *in vitro* susceptibility of subgroup parasite populations.

Materials and Methods

Clinical Isolates

Fresh parasite isolates were obtained from patients with acute *P. falciparum* malaria attending clinics of the Shoklo Malaria Research Unit (SMRU), between 1993 and 2005. The SMRU clinics are all located along 100 km of the Thai-Myanmar border. Isolates were collected from primary infections with a parasite density of at least 5 parasites/1,000 red blood cells. Venous blood (5 ml) was collected into a sterile Vacutainer® tube containing 0.05 ml Potassium-EDTA. Samples were kept at room temperature before being (within the next 4 to 6 hrs) transported to the main laboratory, where they were set up in continuous culture immediately. The fresh parasite isolate samples were obtained as part of prospective clinical evaluations of anti-malarial drug therapy. Written informed consent translated in the patient own language was obtained from each participant, whose signature was witnessed. The studies were approved by the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University.

In vitro Drug Assay

In vitro drug susceptibility was determined by the hypoxanthine uptake inhibition assay, the details of which have been described previously [13]. Briefly, fresh isolates were adjusted to an optimum density of 0.5–1.0% IRBC and a haematocrit of 1.5% using fresh washed group O erythrocytes and complete RPMI-1640 medium with 10% heat-inactivated AB sera. The suspension of infected erythrocytes was dispensed into the wells of a standard microtitre plate containing duplicate serial dilutions of the antimalarial drugs. Serial dilutions for the majority of isolates were measured as the following: 1646.6 to 1.62 nM for mefloquine, 87.0 to 0.044 nM for artesunate, 10255.9 to 10.02 nM for chloroquine, 235.8 to 2.40 nM for lumefantrine; and were made in complete RPMI medium. All drug concentrations, including drug-free controls, were generated in duplicate in 96-well tissue culture plates. The drug-plates were made in bulk and stored at −80°C until use. Following incubation for 24 h, the microtitre plates were pulsed with [3H] hypoxanthine isotopic solution to each well. After a further 18 h incubation, the plates were then harvested. The reproducibility of the EC_{50} measurements was assessed regularly using cloned K1 isolates of *P.falciparum*.

Table 1. Distribution of EC_{50} and slope (γ) values for concentration-effect curves of chloroquine, mefloquine, lumefantrine and artesunate, derived from the two statistical modelling approaches: standard two-stage method and nonlinear mixed-effects modelling.

Anti-malarial drug	Method	EC_{50} Estimate (nM)	95% reference range	Estimate (log_e nM)	SD (log_e nM)	Slope Estimate	95% reference range	Estimate (log_e units)	SD (log_e units)
Chloroquine (n = 421)	STS	230.3†	63.8, 831.3‡	5.44	0.66	3.75†	1.47, 9.53‡	1.32	0.48
	NLME	240.7	68.6, 844.0*	5.48	0.64	4.14	1.85, 9.25*	1.42	0.41
Mefloquine (n = 460)	STS	67.2†	10.0, 450.5‡	4.21	0.97	2.82†	1.07, 7.45‡	1.04	0.50
	NLME	70.4	11.3, 435.6*	4.25	0.93	3.10	1.39, 6.92*	1.13	0.41
Lumefantrine (n = 324)	STS	38.6†	6.4, 234.6‡	3.65	0.92	2.47†	0.86, 7.09‡	0.90	0.54
	NLME	40.7	7.2, 228.0*	3.71	0.88	2.73	1.22, 6.10*	1.00	0.41
Artesunate (n = 474)	STS	2.75†	0.48, 15.7‡	1.01	0.89	5.85†	1.76, 19.46‡	1.77	0.61
	NLME	2.58	0.44, 15.32*	0.95	0.91	5.86	1.70, 20.10*	1.77	0.63

STS – standard two-stage method; NLME – nonlinear mixed-effects modelling; SD – standard deviation for between-isolate variability.
†Geometric mean.
‡Calculated from estimated mean & SD (log_e scale) and converted to original scale.
*95% prediction interval.
doi:10.1371/journal.pone.0069505.t001

Figure 1. Estimated concentration-effect relationship (via nonlinear mixed-effects modelling) for chloroquine, mefloquine, lumefantrine and artesunate, by genotype grouping.
doi:10.1371/journal.pone.0069505.g001

Table 3. Effect of genotype grouping of *Pfmdr1* on EC_{50} for chloroquine, mefloquine, lumefantrine and artesunate using nonlinear mixed-effects modelling.

| EC_{50} | Genotype 1 | Genotype 2 | Genotype 3 | Genotype 4 | Genotype 5 |
| | Single Copy | Single Copy | Single Copy | Double Copy | Triple+ Copy |
	WT[†]	86Y[‡]	1042D[‡]	86N/1042N[‡]	86N/1042N[‡]
Chloroquine [#]					
Percent change	Reference category	44 (14,73)	48 (−4,100)	−10 (−23, 3)	−10 (−28, 7)
Estimated value (nM)	242 (223, 260)	347 (275,419)	359 (233, 483)	217 (184, 248)	217 (174, 260)
No. of isolates	212	20	19	113	57
Mefloquine					
Percent change	Reference category	−59 (−72, −46)	−42 (−67, −17)	139 (102,175)	188 (126,250)
Estimated value (nM)	53.0 (48.0, 58.1)	21.7 (14.7,28.7)	30.9 (17.6,44.1)	126.3 (107.0,145.9)	152.6 (119.8,185.4)
No. of isolates	230	25	24	118	63
Lumefantrine					
Percent change	Reference category	−31 (−62,0)	−57 (−76, −37)	82 (46,119)	75 (28,122)
Estimated value (nM)	35.7 (31.4,39.9)	24.6 (13.6,35.7)	15.5 (8.5,22.5)	65.0 (51.8,78.1)	62.4 (45.6,79.2)
No. of isolates	183	16	17	83	25
Artesunate					
Percent change	Reference category	−17 (−39,6)	38 (−27,102)	63 (35,92)	127 (74,169)
Estimated value (nM)	2.3 (2.1,2.6)	1.8 (1.3,2.3)	3.1 (1.6,4.4)	3.6 (3.1,4.2)	4.9 (3.9,6.2)
No. of isolates	234	24	24	123	69

95% confidence intervals in brackets; [†]Reference group; [#]E_{max} fixed to 0.98; E_0 fixed to 0.01.
Between−isolate variance estimate (standard errors) for EC_{50}: − 0.39(0.026) chloroquine, 0.56(0.043) mefloquine, 0.63(0.050) lumefantrine, 0.67(0.048) artesunate.
Within-isolate variance estimates (standard errors) are:-.
proportional – 0.013(0.0018) chloroquine, 0.010(0.0011) mefloquine, 0.019(0.0020) lumefantrine, 0.025(0.0037) artesunate;
additive – 0.001(0.0002) chloroquine, 0.001(0.0001) mefloquine, 0.0009(0.0002) lumefantrine, 0.0007(0.0002) artesunate.
doi:10.1371/journal.pone.0069505.t003

$$EC_{50.i} = EC_{50} \times \exp(\eta_{i.EC50})$$

$$\gamma_i = \gamma \times \exp(\eta_{i.\gamma})$$

E_{max}, EC_{50} and γ represent the population means and $\eta_{i, Emax}$, $\eta_{i, EC50}$ and $\eta_{i, \gamma}$ are normally distributed random-effects with mean zero and variances Ω_{Emax}, Ω_{EC50} and Ω_{γ}, respectively. Thus the Ωs represent the between-isolate variability for these parameters, reflecting a variety of confounders, including methodological, host and parasite factors that may retain inherent influence within the assay. Between-isolate variability in EC_{50} and γ was assumed to be lognormally distributed; a reasonable assumption since the individual isolate parameter estimates displayed positively skewed distributions and these parameters should always have positive values. Between isolate variability in E_{max} was assumed to be normally distributed since the individual parameter estimates displayed a symmetric distribution. Between isolate variability for E_0 was not incorporated into the model.

Residual variability was modelled with additive and proportional components:

$$E_{ij} = E_{ij}^* + E_{ij}^* \times \varepsilon_{ij.prop} + \varepsilon_{ij.add} \qquad (3)$$

E_{ij} and E_{ij}^* are the observed and predicted normalised percentage uptake of hypoxanthine, respectively, and the residual variability components $\varepsilon_{i,j, prop}$ and $\varepsilon_{i,j,add}$ were assumed to be normally distributed with mean zero and the respective variances σ^2_{prop} and

σ^2_{add}. The nonlinear mixed-effects analysis was performed in NONMEM Version 7.1 (Icon Development Solutions, Ellicott City, MD, USA) in conjunction with the pearl-speaks-NONMEM program (PsN Version 3.5.3; [16,17]), and the corresponding results were compared with the results obtained from the STS approach.

Lastly, a second nonlinear mixed-effects analysis was performed to estimate the effect of genotype grouping on the parameters, EC_{50} and γ. Equations 2 and 3 were used again to analyse data from all isolates simultaneously, but with the following modifications to equation 2:

$$EC_{50.i} = EC_{50}(1 + \theta_1 \times X_1 + \theta_2 \times X_2 + \theta_3 \times X_3 + \theta_4 \times X_4).$$
$$\exp(\eta_{i.EC50})$$

$$\gamma_i = \gamma(1 + \theta_5 \times X_1 + \theta_6 \times X_2 + \theta_7 \times X_3 + \theta_8 \times X_4).\exp(\eta_{i.\gamma})$$

X_1–X_4 are binary indicators (0 = no, 1 = yes) for an isolate with a single copy with mutation at position 86Y (X_1), single copy with mutation at position 1042D (X_2), two copies (all wild types; X_3) or three or more copies (all wild types; X_4), respectively, and θ_1–θ_4 represent the difference in EC_{50} between the groups indicated by X_1–X_4 (respectively) and the group with a single copy with wild type alleles at positions 86N and 1042N. A similar description can be made for θ_5–θ_8 for γ.

Table 4. Results from the pseudo-simulation study comparing the standard two-stage and nonlinear mixed-effects modelling approaches for detecting a binary genotype grouping effect on EC_{50} in studies with 25, 50 or 100 isolates.

Anti-malarial	Analytical approach	Number of Isolates Assessed		
		25	50	100
Mefloquine[†,‡]	STS	85%	100%	100%
	STS (CV ≤15%)◇	85%	98%	100%
	NLME	87%	100%	100%
Lumefantrine[†*]	STS	49%	77%	98%
	STS (CV ≤15%)◇	42%	64%	93%
	NLME	46%	74%	97%

STS - standard two-stage; NLME - nonlinear mixed-effects modelling; CV – coefficient of variation.

Percentage of runs where shift in EC_{50} was detected according to parasite genotype via the likelihood ratio test.

[†]Genotype was grouped as a single wild type (reference category) *versus* wild type with two or more copies.

[‡]For the entire dataset (the assumed population) of isolates with wild type alleles exposed to mefloquine (230 (50%) isolates with a single copy & 181 (39%) with two or more copies), the estimated genotype effect on EC_{50} was 2.60 (ratio of geometric means; 95% CI 2.24 to 3.02) from the standard two-stage approach and 2.55 fold (95% CI 2.32 to 2.78) from the nonlinear mixed-effects modelling approach.

[*]For the entire dataset (the assumed population) of isolates with wild type alleles exposed to lumefantrine (183 (56%) isolates with a single copy & 108 (33%) with two or more copies), the estimated genotype effect on EC_{50} was 1.91 (ratio of geometric means; 95% CI 1.57 to 2.32) from the standard two-stage approach and 1.82 fold (95% CI 1.43 to 2.22) from the nonlinear mixed-effects modelling approach.

◇Only includes those isolates where the coefficient of variation (CV) of the EC_{50} estimate in the first stage of the STS analysis was ≤15% (~84% of total sample for mefloquine & ~76% for lumefantrine).

doi:10.1371/journal.pone.0069505.t004

Simulation Study Comparing Methods for Detecting in vitro Correlates

To compare the STS and nonlinear mixed-effects modelling approaches for detecting genotype grouping effects on EC_{50} in studies with smaller sample size, a simulation study was performed for mefloquine and lumefantrine (these two anti-malarials were selected because they vary in terms of the magnitude of the effect of *pfmdr1* copy number on EC_{50}). To do this a random sample of 25, 50 or 100 isolates was drawn from the entire data set available for each of these drugs. For these isolates, the mean EC_{50} (derived from either STS or nonlinear mixed-effects modelling) was compared between isolates that displayed a single copy (genotype1, above) versus two or more copies (genotypes 4 and 5 above). The prevalence of two or more copies was 39% for the population of isolates for mefloquine and 33% for the lumefantrine isolates.

This process was repeated 100 times, and was considered a "pseudo-simulation" study since step 1 involved drawing random samples from the observed data rather than simulating the data from a statistical model. The proportion of runs where the genotype grouping effect on EC_{50} was detected (via the likelihood ratio test and defined as a p-value <0.05) was compared between the nonlinear mixed-effects modelling and STS approaches for the specified number of isolates (i.e. 25, 50 or 100).

Results

In total 490 isolates were available for statistical analysis of at least one of the anti-malarial drugs tested. Concentration-effect data could be derived from a total of 421 (86%) isolates for chloroquine, 460 (94%) isolates for mefloquine, 324 (66%) isolates for lumefantrine, and 474 (97%) isolates for artesunate. The median number of observations per isolate across all drugs was 22 [range 7 to 44].

Comparison of Standard Two-stage Method and Nonlinear Mixed-effects Modelling

Comparison of the two analytical approaches (STS method and nonlinear mixed-effects modelling) demonstrated that overall the population derived estimates of EC_{50} and slope were similar (see Table 1). Nonlinear mixed-effects modelling yielded slightly lower between-isolate standard deviations (SDs) of the estimates of EC_{50} and slope, with the exception of artesunate, where the SDs were marginally higher.

The proportion of EC_{50} estimates from the STS approach with a coefficient of variation (CV) >15% was 15.4% (65/421) for chloroquine, 16.1% (74/460) for mefloquine, 24.4% (79/324) for lumefantrine and 27.9% (132/474) for artesunate. Isolates with a higher CV had significantly higher EC_{50} values compared to those with CVs below or equal to the 15% threshold (see Table 2).

Estimation of In Vitro Molecular Correlates Using Nonlinear Mixed-effects Modelling

Of the 490 isolates available for statistical analysis, the prevalence of the *pfmdr1* genotype groupings was 49% for single copy wild type (Genotype 1), 5% for single copy number with mutation at position 86Y (Genotype 2), 5% for single copy number with mutation at either positions 1042D (Genotype 3), and 26% for amplification with two copies (Genotype 4) and 15% for three or more copies (Genotype 5). The prevalence for mutation at position 1034C was 3% (5 isolates out of 187).

Single copy number with mutation at position 86Y. Isolates with a single copy number with mutation at position 86Y were associated with a decrease in the EC_{50} value for mefloquine, lumefantrine and artesunate, compared to those with single copy wild type alleles 86N and 1042N. The magnitude of this decrease ranged from 59% for mefloquine, a 31% reduction for lumefantrine and a 17% reduction for artesunate (see Table 3, Figure 1). Conversely, a single copy number with mutation at position 86Y was associated with a relative increase of 44% for the EC_{50} value of chloroquine. In contrast the slope of the effect-concentration curve did not differ significantly for these molecular comparisons (File S2).

Single copy number with mutation at position 1042D. For mefloquine and lumefantrine, isolates with a single copy number with mutations at positions 1042D (Genotype 3) were associated with a decrease in the EC_{50} value compared with single copies of wild type (Genotype 1). The magnitude of this decrease was 42% for mefloquine (population mean estimate of 30.9 versus 53.0 nM) and 57% for lumefantrine (population mean estimate of 15.5 versus 35.7 nM) (see Table 3, Figure 1). Conversely, Genotype 3 variants were associated with a relative increase of 48% for the EC_{50} value of chloroquine (population mean estimate of 359 versus 242 nM). For artesunate a relative increase in the EC_{50} estimate was also observed, however, the 95% confidence interval ranged from a relative decrease of 27% to a relative increase of 102%. As with the variants at codon 86Y, minimal changes in the slope of the concentration-effect profile with the 1042D variant were observed (File S2).

Figure 2. Statistical power by sample size for a comparison of EC_{50} (geometric mean) between two genotypes.
doi:10.1371/journal.pone.0069505.g002

Pfmdr1 Amplification. Isolates with two or more copies of *pfmdr1* were all "wild type" (86N and 1042N). Those with two or three-or-more copies had significantly higher EC_{50} values for mefloquine (139% and 188%, respectively), lumefantrine (82% and 75%, respectively) and artesunate (63% and 127%, respectively) compared with isolates with a single copy wild type (see Table 3, Figure 1). In contrast the mean EC_{50} for chloroquine was similar for isolates irrespective of their copy numbers (Table 3). Compared to single copy isolates, those with two or more copies had steeper slopes of the concentration-effect curves for mefloquine, lumefantrine and artesunate, whereas they were marginally shallower in the chloroquine assay (File S2).

Simulation Study Comparing Standard Two-stage and Nonlinear Mixed-effects Methods for Detecting in vitro Correlates

To assess the power of detecting significantly important shifts in the dose response curve associated with specific parasite genotypes a pseudo-simulation study was conducted using hypothetical study samples of 25, 50 or 100 isolates from a population of wild type isolates where the prevalence of two or more copies was 39% for mefloquine datasets and 33% for lumefantrine datasets.

For both mefloquine and lumefantrine the proportions of studies where the shift associated with genotype was significant was similar for both statistical approaches (see Table 4). As expected the statistical power increased with study size (number of isolates). The effect of *pfmdr1* amplification was more readily apparent for mefloquine, where almost studies of all sample sizes as low as 25 were able to detect a statistically significant relationship. The magnitude of the shift associated with *pfmdr1* amplification was lower with lumefantrine (1.8 fold vs 2.6 for mefloquine) in the

population of isolates, and a corresponding higher sample size (minimum 100 isolates) was required to detect a genotype effect.

When an exclusion criterion based on the precision of the EC_{50} was applied (CV>15%), the statistical power of the STS fell below that of the nonlinear mixed-effects modelling in which all isolates were analysed in the model simultaneously. This loss in statistical power was not observed for mefloquine where the relative effect size of genotype group on EC_{50} was 2.6-fold but was observed for lumefantrine which had an effect size of 1.8 fold; the absolute loss in statistical power ranged from 4 to 10% for sample sizes of 25, 50 and 100.

Statistical Power for Future in vitro Studies

Figure 2 presents the statistical power calculated using formulae for a two-sample comparison of the geometric mean of EC_{50} between two genotype groups. The figure highlights that for genotype groups with a low prevalence (e.g. 10%, similar to what was observed in this study population for single copy with mutation at positions 86Y or 1042D) a larger number of isolates would be required to achieve 80% statistical power for detecting a genotype effect of 1.5 fold (430 total isolates required of which 43 will have genotype group1 and 387 genotype group2), 2 fold (150 total isolates) and 2.5 fold (80 total isolates). As the prevalence of genotype group increases the total sample size required to achieve 80% statistical power decreases, however, to detect a genotype effect of 1.5 fold (which may be of clinical importance) 245 isolates are required if the prevalence of genotype is 20%, 174 isolates if prevalence is 33% and 156 isolates if the prevalence is 50%.

Discussion

The primary aim of *in vitro* drug susceptibility testing of Plasmodia is to derive estimates of drug activity independent

from the host and pharmaceutical factors known to confound *in vivo* efficacy studies. Several *in vitro* approaches have been established and validated although all remain vulnerable to a variety of methodological factors that are manifest in inherent within- and between- assay variability. In the current study data from a large number of clinical isolates of *P. falciparum* from the western border of Thailand were used to define the correlation of *in vitro* drug susceptibility of four antimalarial drugs with polymorphisms of the *pfmdr1* gene, known to be a key determinant of multidrug resistance [11,12]. Our results provide precise estimates of the shifts in drug susceptibility confirming previous observations that single nucleotide polymorphisms of *pfmdr1* are associated with decreased susceptibility to chloroquine but increased susceptibility to artesunate, mefloquine and lumefantrine. Whereas increased *pfmdr1* copy number was associated with reduced susceptibility to artesunate, mefloquine and lumefantrine.

The main focus of the study was to compare two statistical approaches for estimating drug susceptibility parameters and assess their relative merits for defining between-isolate variability and validating putative molecular markers of antimalarial drug resistance. Our results demonstrate that the STS approach and nonlinear mixed-effects modelling provided very similar population estimates of EC_{50}s, however the STS was particularly vulnerable to exclusion of isolates with poor precision. Between 15–28% of isolates were excluded from the STS analysis and since these isolates were more likely to be highly resistant isolates, the inevitable consequence was an under-estimation of the population mean EC_{50}.

The *in vitro* data used in this study were derived from rich balanced designs compared to the sparse and unbalanced designs commonly observed for anti-malarial pharmacokinetic studies [18–20]. Separation of the within and between-isolate variance components in the nonlinear mixed-effects model provided minimal reductions in the between-isolate variability for the model parameters of three of the four drugs assessed, therefore the method did not result in greater statistical power for detecting the genotype effect on EC_{50}.

In the nonlinear regression analyses using the STS approach the lower precision of the EC_{50} estimates was likely an artefact of the design of the *in vitro* experiment in which doubling dilutions of drug concentrations is applied, resulting in fewer measurements and larger intervals at higher drug concentrations [5]. Ideally such isolates should be retested with a higher series of drug dilutions. However, without culture adaptation of the parasite this is usually not feasible. Instead such isolates are often simply excluded from the STS approach, with inevitable reduction in the estimate of the overall population EC_{50} and the possibility of missing the early detection of resistance emergence. Although nonlinear mixed-effects modelling cannot overcome inclusion criteria for the assay itself, it does offer advantages over the STS approach by including all isolates in the analysis simultaneously to ensure each isolate contributes some information towards estimation of the parameters. In this approach the within-isolate variability is determined, thus, drug susceptibility estimates are derived after controlling for lab covariates such a parasite staging, assay duration and different batches of drug plates [21]. Further, those isolates with less reliable individual data (e.g. resistant isolates with no measurements between the concentrations associated with maximum and minimum effect) do not contribute the same amount of information as other isolates (i.e. not all isolates are weighted equally in the model). Conversely the STS approach weights the individual isolate-specific estimates equally. This can be problematic since it has been shown in the separate isolate-specific nonlinear regressions (i.e. stage 1 of the analysis which takes no

account of the other isolates in the population) that the most resistant isolates tend to have EC_{50}s overestimated as curve fitting estimates the EC_{50} to be approximately the mid-point between two concentrations with very different effect measurements [5].

The nonlinear mixed-effects modelling approach allowed a comprehensive analysis of the *in vitro* – molecular correlation for four major antimalarial drugs. Our findings confirm the role of *pfmdr1* copy number and reduced drug susceptibility to mefloquine, lumefantrine and artesunate [10–12,22], the effect ranging from 63 to 188%. Whereas an increase from 2 to 3 or more copies resulted in further increments of mefloquine and artesunate this was not apparent for lumefantrine. We also estimated the change in both the EC_{50} and slope of the effect-concentration curve due to single nucleotide polymorphisms at 86Y and 1042D. These mutations occurred almost entirely in isolates with a single copy of *pfmdr1*, and were associated with a modest increase in the EC_{50} of chloroquine (44 to 48%). Such estimates can be used for predictions of isolate specific effect-concentration profiles for different genotype groups, and included in within-host pharmacokinetic-pharmacodynamic models [23] and population level anti-malarial resistance models [24].

Our results highlight the challenges of validating candidate markers of drug resistance. The power to detect statistical significance depends upon the shift in the dose response curve, and the prevalence of the genotype in the population. There may be a tendency to dismiss important correlates that are confounded by inadequate sample size or sample bias. Our sample size calculations demonstrate that in order to achieve 80% power to detect an *in vitro* – molecular effect of a genetic mutation with a prevalence of 10% and a 1.5 fold shift in the EC_{50}, a sample size of 430 isolates would be required. Whereas a mutation with a greater effect such as *pfmdr1* copy number on mefloquine sensitivity would be detected with a much smaller sample size (eg only 25 isolates required for an effect size of 2.5 fold and a prevalence of genotype in the population of 50%).

In conclusion, our comparison of the conventional STS approach versus the more sophisticated nonlinear mixed-effects modelling, for the analysis of *in vitro* drug susceptibility data, did not demonstrate any major advantage of applying nonlinear mixed-effects modelling providing data were generated from multiple drug concentrations around the EC_{50}, over the most dynamic part of the dose response curve. However, when sporadic isolates with high resistance and low precision were present within a parasite population the nonlinear mixed-effects model estimates were likely to be less biased, and provide greater power at detecting *in vitro* - molecular correlates of candidate molecular markers of drug resistance.

Supporting Information

File S1 *In vitro* **drug susceptibility data and *pfmdr1* polymorphisms of all isolates included in the analysis.** Drug susceptibility data presented were generated from the standard two-stage regression analysis.
(XLSX)

File S2 **Effect of genotype grouping of *Pfmdr1* on slope values for chloroquine, mefloquine, lumefantrine and artesunate using nonlinear mixed-effects modeling.**
(PDF)

Acknowledgments

Author Contributions

Conceived and designed the experiments: TJCA NJW FN RNP CW. Performed the experiments: TJCA SN RNP. Analyzed the data: JAS KMJ SZ RNP. Wrote the paper: JAS KMJ RNP TJCA. Revising the article critically: NJW CW FN.

References

1. Grimberg BT (2011) Methodology and application of flow cytometry for investigation of human malaria parasites. J Immunol Methods 367: 1–16.
2. Kosaisavee V, Suwanarusk R, Nosten F, Kyle DE, Barrends M, et al. (2006) *Plasmodium vivax*: isotopic, PicoGreen, and microscopic assays for measuring chloroquine sensitivity in fresh and cryopreserved isolates. Exp Parasitol 114: 34–39.
3. Noedl H, Wongsrichanalai C, Wernsdorfer WH (2003) Malaria drug-sensitivity testing: new assays, new perspectives. Trends Parasitol 19: 175–181.
4. Steimer JL, Mallet A, Golmard JL, Boisvieux JF (1984) Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev 15: 265–292.
5. Stepniewska K, Chotivanich K, Brockman A, Day NP, White NJ (2007) Overestimating resistance in field testing of malaria parasites: simple methods for estimating high EC50 values using a Bayesian approach. Malar J 6: 4.
6. Anderson TJ, Nair S, Qin H, Singlam S, Brockman A, et al. (2005) Are transporter genes other than the chloroquine resistance locus (*pfcrt*) and multidrug resistance gene (*pfmdr*) associated with antimalarial drug resistance? Antimicrob Agents Chemother 49: 2180–2188.
7. Davidian M, Giltinan DM (1995) Nonlinear Models for Repeated Measurement Data. London: Chapman & Hall.
8. Aarons L (1996) Population approaches/sparse data analysis for human variability in kinetics and dynamics. Environ Toxicol Pharmacol 2: 197–199.
9. Simpson JA, Aarons L, White NJ (2001) How can we do pharmacokinetic studies in the tropics? Trans R Soc Trop Med Hyg 95: 347–351.
10. Price RN, Uhlemann AC, Vugt M, Brockman A, Hutagalung R, et al. (2006) Molecular and Pharmacological Determinants of the Therapeutic Response to Artemether-Lumefantrine in Multidrug-Resistant *Plasmodium falciparum* Malaria. Clin Infect Dis 42: 1570–1577.
11. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, et al. (2004) Mefloquine resistance in *Plasmodium falciparum* and increased *pfmdr1* gene copy number. Lancet 364: 438–447.
12. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF (2000) *Pgh1* modulates sensitivity and resistance to multiple antimalarials in *Plasmodium falciparum*. Nature 403: 906–909.
13. Brockman A, Price RN, van Vugt M, Heppner DG, Walsh D, et al. (2000) *Plasmodium falciparum* antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg 94: 537–544.
14. Price RN, Cassar C, Brockman A, Duraisingh M, van Vugt M, et al. (1999) The *pfmdr1* gene is associated with a multidrug-resistant phenotype in *Plasmodium falciparum* from the western border of Thailand. Antimicrob Agents Chemother 43: 2943–2949.
15. Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, et al. (2009) Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 4: e4551.
16. Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN)–a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75: 85–94.
17. Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-Toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79: 241–257.
18. Ashley EA, Stepniewska K, Lindegardh N, McGready R, Hutagalung R, et al. (2006) Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria. Antimicrob Agents Chemother 50: 2281–2285.
19. Jullien V, Ogutu B, Juma E, Carn G, Obonyo C, et al. (2010) Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy. Antimicrob Agents Chemother 54: 2611–2617.
20. Simpson JA, Hughes D, Manyando C, Bojang K, Aarons L, et al. (2006) Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. Br J Clin Pharmacol 61: 289–300.
21. Russell B, Chalfein F, Prasetyorini B, Kenangalem E, Piera K, et al. (2008) Determinants of *in vitro* drug susceptibility testing of Plasmodium vivax. Antimicrob Agents Chemother 52: 1040–1045.
22. Pickard AL, Wongsrichanalai C, Purfield A, Kamwendo D, Emery K, et al. (2003) Resistance to antimalarials in Southeast Asia and genetic polymorphisms in *pfmdr1*. Antimicrob Agents Chemother 47: 2418–2423.
23. Zaloumis S, Humberstone A, Charman SA, Price RN, Moehrle J, et al. (2012) Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Malar J 11: 303.
24. Pongtavornpinyo W, Hastings IM, Dondorp A, White LJ, Maude RJ, et al. (2009) Probability of emergence of antimalarial resistance in different stages of the parasite life cycle. Evol Appl 2: 52–61.